WienkersLCAllieviCHauerMJWynaldaMA. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos1999;7:1334–40.
2.
DeVaneCL. Differential pharmacology of newer antidepressants. J Clin Psychiatry1998;59(suppl 20):85–93.
3.
CacciaS. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet1998;4:281–302.
4.
FleishakerJCHermanBDPearsonLKIonitaAMucciM. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clin Drug Invest1999;18:141–50.
5.
DostertPBenedettiMSPoggesiI. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol1997;7(suppl 1):23S–35S.
6.
KatonaCBercoffEChiuETackPVersianiMWoelkH. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomized trial. J Affect Disord1999;55:203–13.
7.
BerzewskiHVan MoffaertMGagianoCA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol1997;(suppl 1):37S–47S.
8.
LefkowitzRJHoffmanBBTaylorP. Neurotransmission. The autonomic and somatic motor nervous systems. In: HardmanJGLimbirdLEMolinoffPBRuddonRWGilmanGoodman A, editors. Goodman & Gilman's The pharmacological basis of therapeutics, ninth ed.New York: McGraw-Hill; 1996. p 105–39.
9.
MillsKC. Serotonin syndrome. Crit Care Clin1997;13(4):763–83.
10.
SzymanskiLKingBH. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. J Am Acad Child Adolesc Psychiatry1999;38(12 Suppl):5S–31S.
11.
MarcotteD. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord1998;50:245–51.
12.
Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialities, 34th edition.Ottawa: Canadian Pharmacists Association; 1999.
13.
BjoroKGjerstadLOysteinBOsnesSSchrumpfE. Topiramate and fulminant liver failure [letter]. Lancet1998;352:1119.
14.
KucharzEJ. Edmund Biernacki and the erythrocyte sedimentation rate. Lancet1987;1:696.
15.
TomerYShoenfeldY. The erythrocyte sedimentation rate in modern medicine. Harefuah1991;120:199–203.
16.
AnfinsonTJKatholRG. Screening laboratory evaluation in psychiatric patients: A review. Gen Hosp Psychiatry1992;14:248–57.
17.
MaesMDelangeJRanjanRMeltzerHYDesnyderR, Cooremans W, and others. Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res1997;5:1–11.
18.
SirotaP. Is schizophrenia an autoimmune disease?Isr J Med Sci1990;26:694–7.
19.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.Washington (DC): APA; 1995.
20.
KraepelinE. Die Schreckneurosen. In: BarthJA, editor. Ein lehrbuch für studieren und aertze, Vol II. Leipzig: 1899.
21.
SheehanDVLecrubierYSheehanKHAmorimPJanavsJ, Weiller E, and others. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry1998;59(suppl 20):22–33. Quiz 34–57.
22.
MisriSKostarasDKostarasX. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: Current knowledge. Can J Psychiatry2000;45:285–7.
23.
WisnerKLGelenbergAJLeonardHZarinDFrankE. Pharmacologic treatment of depression during pregnancy. JAMA1999;282:1264–9.
24.
ChambersCDJohnsonKADickLMFelixRJJonesKL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med1996;335:1010–5.
25.
AltshulerLLCohenLSzubaMPBurtVKGitlinMMintzJ. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry1996;153:592–606.
26.
MisriSKostarasDKostarasX. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: Current knowledge. Can J Psychiatry2000;45:285–7.
27.
LohrJBFlynnK. Smoking and schizophrenia. Schizophr Res1992;8:93–102.
28.
McEvoyJP. Smoking and schizophrenia. Drug Development Research1996;38:263–6.
29.
de LeonJ. Smoking and vulnerability for schizophrenia. Schizophr Bull1996;22:405–9.
30.
GoffDCHendersonDDAmicoE. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry1992;149:1189–94.
31.
HareE. Schizophrenia as a recent disease. Br J Psychiatry1988;153:521–31.
32.
HareE. Aspects of the epidemiology of schizophrenia. Br J Psychiatry1986;149:554–61.
33.
DohanFC. Wartime changes for hospital admissions for schizophrenia. Acta Psychiatr Scand1966;42:1–23.
34.
MilmoreBKConoverAG. Tobacco consumption in the United States. 1880–1955. Public Health Monograph No.45;1956:107–11.
35.
JaffeJH. Drug addiction and drug abuse. In GilmanAGRallTWNiesASTaylorP, editors. The pharmacological basis of therapeutics. 8th ed.New York: McGraw Hill; 1993. p 545–8.
36.
JoycePR. Changing trends in first admissions and re-admissions of mania and schizophrenia in New Zealand. Aust N Z J Psychiatry1987;21:82–6.
37.
BlandRC. Clinical features of affective disorders. I: Diagnosis, classification, rating scales, outcome and epidemiology. In: DewhurstWGBakerGB, editors. Pharmacotherapy of affective disorders: Theory and practice. London: Croom Helm; 1985.
38.
SalemJEKringAM. The role of gender differences in the reduction of etiological heterogeneity in schizophrenia. Clin Psychol Rev1998;18:795–819.
39.
AlbusMMaierW. Lack of gender differences in age at onset in familial schizophrenia. Schizophr Res1995;18:51–7.
40.
HillAB. The environment and disease: Association or causation?Proc Roy Soc Med1965;58:295–300.
41.
GoodmanECapitmanJ. Depressive symptoms and cigarette smoking among teens. Pediatrics2000;106:748–55.
42.
BeamishPKilohLG, Psychoses due to amphetamine consumption. J Ment Sci1960;10:337–43.
43.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.Washington (DC.): American Psychiatric Association; 1994.
44.
KraepelinE. Dementia Praecox and Paraphrenia. Barclay RM, trans. New York: Krieger Publishing Company; 1971.
45.
HaysP. The nosological status of schizophrenia. Lancet1984;1:1342–5.
RippeJMIrwinRSFinkMPCerraFB. Disorders of temperature control: Hyperthermia. In: CurleyFJ and IrwinRS, editors. Intensive Care Medicine. Volume 1. Boston: Brown and Company; 1996. p 859–74.
